Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of switching from metreleptin to mibavademab in generalized lipodystrophy
2026-000121-16Phase 3
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mibavademab in congenital generalized lipodystrophy (CGL) and inborn error of lipid metabolism, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs).
02
Drugs
mibavademab
03
Conditions
congenital generalized lipodystrophy (CGL)inborn error of lipid metabolism
Beyond the preview
Go deeper on 2026-000121-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000121-16.